drugset / Trial / NCT07495930
Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®
RandomizedParallel-groupDouble-blindTreatment
Summary
The study is being conducted to compare the pharmacokinetic (PK) parameters of HLX319 and EU-Phesgo® after a single subcutaneous administration in healthy male subjects in China, providing a basis for the design of subsequent clinical study protocols.
Timeline
- Start
- 2026-04-30
- Primary completion
- 2026-07-01
- Completion
- 2026-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | EU-Phesgo | Monoclonal antibody | — | Subcutaneous |
| Subject | HLX319 | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.